Supplementary Table 1. Characteristics with regards to 30-day mortality

Patient characteristics	Total patient cohort (N=135)	Survivors (N=105)	Non-Survivors (N=30)	p-value
Demographics				
Age (years) (mean, SD)	64·6 (19·5)	60·0 (18·9)	80·7 (11·6)	1.22×10^{-11}
Male gender (N, %)	70 (51·9%)	56 (53·3%)	14 (46·7%)	0·6547
Disease progression and mortality				
Non-Invasive Ventilation (N, %)	23 (17·04%)	14 (13·3%)	9 (30·0%)	0·0511
Intensive care unit admission (N, %)	31 (22·96%)	25 (23·8%)	6 (20·0%)	0·7010
Invasive Ventilation (N, %)	16 (11·85%)	12 (11·4%)	4 (13·3%)	0·6366
30-day mortality (N, %)	30 (22·22%)			
Hospital length of stay (days)(median, Q1-Q3)	8 [3 - 17]	8 [2 – 17]	11·5 [5·25 – 15·75]	0·0722
Comorbidities				
Cardiovascular disease (N, %)	75 (55·6%)	52 (49·5%)	23 (76·7%)	0·0786
Respiratory disease (N, %)	35 (25·9%)	30 (28·6%)	5 (16·7%)	0·2587
Haematological disease (N, %)	5 (3·7%)	5 (4·8%)	0 (0·0%)	0·2320
Immunodeficiency (N, %)	5 (3·7%)	5 (4·8%)	0 (0·0%)	0·2320
Diabetes (N, %)	32 (23·7%)	26 (24·8%)	6 (20·0%)	0·6366
Renal Disease (N, %)	23 (17·0%)	13 (12·4%)	10 (33·3%)	0·0142
Liver Disease (N, %)	9 (6·7%)	8 (7·6%)	1 (3·3%)	0·4227
Malignancy (N, %)	20 (14·8%)	14 (13·3%)	6 (20·0%)	0·4028
Central Nervous System Disease (N, %)	27 (20·0%)	16 (15·2%)	11 (36·7%)	0·0206
Biomarker concentrations				
CRP[1] (mg/L) (median, Q1-Q3)	59 [17 - 143]	52 [13 - 143]	102 [43 – 148·75]	0·0301
White Cell Count (10^9/L) (median, Q1-Q3)	7·1 [5·2 – 9·65]	7·1 [5·5 – 9·7]	7·0 [4·425 – 8·675]	0·1469
Neutrophil Count (10^9/L) (median, Q1-Q3)	5·31 [3·51 – 7·66]	5·33 [3·72 – 8·0]	5·23 [3·235 – 6·8475]	0·2005
Lymphocyte Count (10^9/L) (median, Q1-Q3)	0·98 [0·70 – 1·36]	0·99 [0·74 – 1·41]	0·845 [0·5675 – 1·2675]	0·1469
PCT[2] (ng/mL) (median, Q1-Q3)	0·13 [0·07 - 0·41]	0·12 [0·07 - 0·2853]	0·3595 [0·09 – 0·5575]	0·0307
MR-proADM (nmol/L) (median, Q1-Q3)	1·02 [0·71 - 1·61]	0·899 [0·6284 - 1·316]	1·842 [1·3943 – 2·6323]	<0·00001

[1] C-reactive protein

[2] Procalcitonin